$1.44
-0.02 (-1.37%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where INM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 2 tracked-famous managers (JANE STREET GROUP, LLC, CITADEL ADVISORS LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · insider 90d: 16 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| INM-755 (Cannabinol) Cream for Treatment of Epidermolysis BullosaNCT04908215Change from Baseline in Non-Wound Itch by Visual Analogue Scale (VAS)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: INM-755 (cannabinol) cream, Vehicle Cream | Epidermolysis Bullosa Simplex, Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica, Kindler Syndrome | 19 | 2023-04-03actual | 2023-07-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19